New Pharmacological Approaches to Target PCSK9

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Genetics

Background:

• Proprotein convertase subtilisin kexin 9 (PCSK9) regulates LDL-C by inhibiting hepatic LDL receptor recycling.
• PCSK9 gene variants influence LDL-C levels and cardiovascular risk; loss-of-function variants decrease risk, while gain-of-function variants increase it.
• PCSK9 inhibition is a validated strategy for managing hypercholesterolemia.

Purpose of the Study:

• To review current strategies targeting PCSK9 for hypercholesterolemia treatment.
• To discuss the clinical outcomes of emerging PCSK9-targeting approaches.

Main Methods:

• Review of approved and investigational PCSK9 inhibitors.
• Analysis of clinical trial data for monoclonal antibodies and gene silencing therapies.
• Exploration of preclinical approaches including peptide vaccines and small molecule inhibitors.

Main Results:

• Monoclonal antibodies (evolocumab, alirocumab) and gene silencing (inclisiran) are effective PCSK9 inhibitors.
• Inclisiran offers less frequent dosing (twice yearly) and is under evaluation.
• Novel approaches like peptide vaccines and oral inhibitors are in preclinical development.

Conclusions:

• PCSK9-targeting therapies are advancing, offering new options for hypercholesterolemia and high cardiovascular risk patients.
• The field is moving towards more convenient and potentially cost-effective treatments.
• Continued innovation in PCSK9 inhibition promises significant clinical impact.